SATURDAY, OCTOBER 6

1415-1605

MP-09—Prostate Cancer - Intervention
Room: 5F Goguryeo 2

MP-09.01
Are the CHAARTED and LATITUDE Risk Classifications Applicable? An Asian Perspective
Clarissa Gurbani, Singapore

MP-09.02
Radical Prostatectomy Versus Non-Local Treatment in the Management of Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis
Limin Zhang, China

MP-09.03
Serum Neuroendocrine Markers Guide Treatment Sequence Selection in Metastatic Castration-Resistant Prostate Cancer Patients
Xiaoguang Shao, Republic of China (Taiwan)

MP-09.04
Near-infrared Fluorescence and Indocyanine Green: A Helpful Technique to Identify the Benchmark Artery of Neurovascular Bundle During Robot-assisted Radical Prostatectomy
Nordine Amara, France

MP-09.05
Neoadjuvant Docetaxel plus Goserelin in Patients with Very-High Risk, Locally Advanced Prostate Cancer: Initial Results From a Randomized Study
Yuan-Yuan Qu, China

MP-09.06
Detection of Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA from Japanese Castration-Resistant Prostate Cancer Patients
Takayuki Sumiyoshi, Japan

MP-09.07
To Evaluate the Reset Level of Serum Prostate Specific Antigen after Enucleation of the Prostate in Predicting the Risk of Latent Prostate Cancer
Yung-Ting Cheng, China

MP-09.08
Oncological Outcomes of Focal Irreversible Electroporation as Primary Treatment for Clinically Significant Localized Prostate Cancer
Alexandar Blazevski, Australia

MP-09.09
Feasibility of Real-Time Pelvic Sphincterial Electromyographic Monitoring During Laparoscopic Radical Prostatectomy
Jie Situ, China

MP-09.10
MRI-Guided Transurethral Ultrasound Ablation in Patients with Localized Prostate Cancer: 3-Year Outcomes of a Prospective Phase I Study
Joseph L. Chin, Canada

MP-09.11
Inverse Stage Migration Patterns in North American Patients Undergoing Local Prostate Cancer Treatment: A Contemporary Population-Based Update in Light of the 2012 USPSTF Recommendations
Sami-Ramzi Leyh-Bannurah, Germany

MP-09.12
Urinary Catheter Removal after Minimally Invasive Radical Prostatectomy: 1 Day is Enough
Sergey Reva, Russia

MP-09.13
Salvage High-Intensity Focused Ultrasound for Locally Recurrent Prostate Cancer after Low-Dose-Rate Brachytherapy: Oncologic and Functional Outcomes.
Thomas Hostiou, France

MP-09.14
Follow-Up in Active Surveillance for Prostate Cancer: Variety in Dutch Practice Patterns
Timo Soeterik, Netherlands

MP-09.15
The Role of Pelvic Lymph Node Dissection on the Oncologic Outcomes in the Patients with cN0 High-Risk Prostate Cancer
Won Sik Ham, South Korea

MP-09.16
Predictive Value of Gene Signature in Biochemical Recurrence Prostate Cancer
Dingwei Ye, China

MP-09.17
Molecular Stratification of Prostate Cancer by Gleason Score 6 to 8 Reveals Distinct Intermediate Risk Patterns
Fangning Wan, China

MP-09.18
Prediction of Early Biochemical Recurrence after Radical Prostatectomy Based on Molecular Composition Analyzing of Preoperative Plasma Using Surface-Enhanced Raman Spectroscopy
Xiaoguang Shao, China

MP-09.19
Impact of Lymph Node Metastases on Prognosis After Radical Prostatectomy for Patients with Oligometastatic Prostate Cancer
Doo Yong Chung, South Korea

MP-09.20
Extended Radical Prostatectomy Following Neoadjuvant Chemohormononal Therapy (Low Dose Estrmustine + LHRH Agonist/Antagonist) for Patients with High Risk Localized Prostate Cancer
Hideki Enokida, Japan

MP-09.21
Clonal Evolution and the Role of Serial Liquid Biopsies in Low PSA and High-Grade Prostate Cancer Patients
Jing Li, China

MP-09.22
Robot-Assisted Radical Prostatectomy for High Risk Prostate Cancer: An Analysis of Positive Surgical Margin Rates
Shuang Huang, China

MP-09.23
Poor Outcomes with High Ductal Proportion: The Link between Morphometry and Biochemical Recurrence of Prostate Ductal Adenocarcinoma
Timothy Harkin, Australia

MP-09.24
Safety and Efficacy of Pelvic Autonomic Nerve Monitoring During Robot-Assisted Laparoscopic Radical Prostatectomy (RALP) by Human Clinical Trial
Won Hoon Song, South Korea

MP-09.25
TBX1 Promotes Neuroendocrine Transdifferentiation of Prostate Cancer Via CYP1B1
Fajun Qu, China

MP-09.26
The Clinical Significance of Serum Amyloid Protein A Determination in Prostate Cancer Patients
Yan Dongliang, China

MP-09.27
Effects of RNA Interference and GOLPH3 Silence on the Biological Behavior of Prostate Cancer Cell PC-3
Shibo Fu, China